

RESEARCH & DEVELOPMENT

PhenoPath's scientific team strives to create an environment of collaboration with our clients. Our team stands ready to support the client's projects including development, optimization and validation of specialty pathology assays for use in biomarker discovery, drug development, diagnosis, and clinical trial applications.

METHOD DEVELOPMENT

VALIDATION

- Carefully selected antibodies target tissue-specific markers, tumor prognostic and predictive markers, surrogate markers of chromosomal translocations, and a broad range of esoteric antigens
- Validation protocols include testing for specificity, sensitivity and reproducibility. Accuracy, precision, reportable range, reference intervals, co-localization, or concordance are evaluated, if relevant
- Technology transfers include development of detailed procedures and creation of project-specific SOPs, if applicable
- Controls and/or tissues are tested with alternative technology, when appropriate
- Technology transfers include verification and/or validation of the procedures and creation of project-specific SOPs, if applicable
- Comprehensive validation reports are provided
- PhenoPath commonly uses human, animal, xenografts, and patient-derived xenografts in our clinical studies

METHOD DEVELOPMENT - IHC

- Antigen retrieval methods, antibody titer and detection systems are optimized
- Antibodies can be tested on whole tissue sections, tissue microarrays, cell culture pellets, or xenografts

METHOD DEVELOPMENT - FLOW CYTOMETRY

- Up to 10-color custom assays may be designed for surface or intracellular antigens
- Internal positive and negative control populations are generally used, but if not available, isotype-matched controls can be utilized



EXPERTISE SOLID TUMOR PATHOLOGY HEMATOPATHOLOGY Diagnosis and subtyping (breast, colon, lung, sarcoma, etc.) Indolent B cell non-Hodgkin lymphoma Undifferentiated malignant neoplasms Prognostic and predictive markers Carcinomas of unknown primary site Aggressive B cell non-Hodgkin lymphoma Spindle cell tumors/sarcoma subtyping T cell non-Hodgkin lymphoma Mesothelioma vs. adenocarcinoma Lymphoblastic leukemia / lymphoma Small, blue, round cell tumors Hodgkin lymphoma Germ cell neoplasms Plasma cell neoplasms Acute myeloid leukemias Skin and mucosal immunofluorescence studies

Rare hematolymphoid neoplasms

Benign hematolymphoid proliferations

TESTING CAPABILITIES

IHC, IF, DNA/RNA ISH, RNAScope	IMAGING & QUANTIFICATION
Dako Link 48	Aperio AT2
Dako Omnus	PerkinElmer Nuance inForm Multispectral Imaging
Ventana Benchmark Ultra	PCR
Ventana Benchmark Discovery	Bio-Rad CFX96
BioCare Intellipath	Roche cobas z 480
Leica Bond-Max	Qiagen Rotor-Gene Q
10-color FLOW CYTOMETRY	FISH / CYTOGENETICS
Beckman Coulter Gallios TM	MetaSystems Metafer 4

SERVICE DELIVERY

PROJECT MANAGEMENT	DATA MANAGEMENT
Central point of contact	Customized database development
Coordination of all delivery groups	Virtual pathology reporting capabilities
Structured processes	Secure and encrypted data transfer and archiving
GLOBAL LOGISTICS	REGULATORY COMPLIANCE
Sample integrity and security	CAP Accreditation / CLIA Certificate
International and domestic shipping capabilities	Permits and Licenses: NY, CA, MD, FL, RI
Long-term specimens storage	Studies performed in accordance with GLP/GCP, as applicable



Chronic myeloid neoplasms (MDS & MPN)

Hydatidiform mole evaluation

Amyloid subtyping

Contact Us: 888-927-4366 www.phenopath.com